SCHEMBL676303

SCHEMBL676303

NC(CCC[C@H](N)C(=O)O)C(=O)OCc1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC1A1 P43005 4/20 0.52
SLC1A3 P43003 3/20 0.52
ALPI P09923 1/20 0.51
PKM P14618 1/20 0.51
PTGS1 P23219 1/20 0.51
XIAP P98170 1/20 0.51
SLC7A5 Q01650 1/20 0.51
IDO1 P14902 2/20 0.50
LTA4H P09960 2/20 0.48
SLC15A1 P46059 1/20 0.48
GRIK1 P39086 1/20 0.48
KMT2A Q03164 3/20 0.47
SLC1A2 P43004 2/20 0.47
MEN1 O00255 1/20 0.47
CYP1A2 P05177 1/20 0.47
CYP2D6 P10635 1/20 0.47
CYP2C9 P11712 1/20 0.47
CYP2C19 P33261 1/20 0.47
ALDH1A1 P00352 3/20 0.47
TDP1 Q9NUW8 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30466149 1.00 SLC1A1 (0.52) SLC1A1SLC1A3ALPIPKMPTGS1
SCHEMBL10591983 1.00 SLC1A1 (0.52) SLC1A1SLC1A3ALPIPKMPTGS1
SCHEMBL10994023 1.00 SLC1A1 (0.52) SLC1A1SLC1A3ALPIPKMPTGS1
SCHEMBL7754254 1.00 SLC1A1 (0.52) SLC1A1SLC1A3ALPIPKMPTGS1
SCHEMBL4161005 0.95 IDO1 (0.53) SLC1A1SLC1A3ALPIPKMPTGS1
SCHEMBL10441465 0.95 IDO1 (0.53) SLC1A1SLC1A3ALPIPKMPTGS1
SCHEMBL3471267 0.93 SLC1A1 (0.55) SLC1A1SLC1A3ALPIPKMPTGS1
SCHEMBL28361329 0.93 SLC1A1 (0.55) SLC1A1SLC1A3ALPIPKMPTGS1
Hydrochloric Acid SCHEMBL28986973 0.93 IDO1 (0.52) SLC1A1SLC1A3ALPIPKMPTGS1
SCHEMBL5618771 0.93 SLC1A1 (0.55) SLC1A1SLC1A3ALPIPKMPTGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 199 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250243472-A1 MODIFIED HELICASES OXFORD NANOPORE TECHNOLOGIES PLC (GB) 2025-07-31 US claimed
CN-118986933-A Nanometer preparation for delivering medicine on demand aiming at inherent barrier of pancreatic cancer, and preparation method and application thereof 复旦大学 2024-11-22 CN claimed
CN-118903052-A Stimulus response type nanocapsule for delivering PROTAC, preparation method and application 复旦大学 2024-11-08 CN claimed
CN-118459755-B Gemcitabine nano prodrug with stable circulation and preparation method and application thereof 复旦大学 2024-10-11 CN claimed
CN-116509801-B Hypoxia response drug delivery micelle adapting to pancreatic cancer microenvironment and preparation method thereof 复旦大学 2024-07-05 CN claimed
CN-118256603-A Modified enzymes 牛津纳米孔科技公开有限公司 2024-06-28 CN claimed
CN-116509801-A Hypoxia response drug delivery micelle adapting to pancreatic cancer microenvironment and preparation method thereof 复旦大学 2023-08-01 CN claimed
CN-108912324-A A kind of inner membrance is the polyester peptide vesica and the preparation method and application thereof of positive electricity 苏州大学 2018-11-30 CN claimed
US-20150166786-A1 POLY((LACTIC-CO-GLYCOLIC ACID)-B-LYSINE) AND PROCESS FOR SYNTHESIZING A BLOCK COPOLYMER OF PLGA AND PLL (POLY-E-CBZ-L-LYSINE) InVivo Therapeutics Corp. (US) 2015-06-18 US claimed
US-8735093-B2 Mutant pyrrolysyl-tRNA synthetase, and method for production of protein having non-natural amino acid integrated therein by using the same RIKEN (JP) 2014-05-27 US claimed
EP-2046733-B1 PROCESS FOR THE PREPARATION OF EPSILON-ALKOXYCARBONYLLYSINES AND THEIR ANALOGUES ITALIANA SINT SPA (IT) 2011-10-05 EP claimed
US-7968519-B2 Amido-containing metal complexes; sonication; for self-assembling polypeptides; vesicles THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2011-06-28 US claimed
US-20080125581-A1 Methods and compositions for controlled polypeptide synthesis NAVY, SECRETARY OF THE UNITED STATES OF AMERICA 2008-05-29 US claimed
EP-0709373-B1 PYRROLIDINE DERIVATIVE ZAIDAN HOJIN BISEIBUTSU (JP) 2001-10-17 EP claimed
US-4842924-A HIGH COMPRESSIVE, TENSILE STRENGTH FARRIS RICHARD J (US) 1989-06-27 US claimed
JP-62270619-A None JP disclosed
CN-122029203-A Novel enzymes 牛津纳米孔科技公开有限公司 2026-05-12 CN disclosed
US-4578219-A CONTRACEPTIVE VACCINE NORTHWESTERN UNIVERSITY (US) 1986-03-25 US disclosed
EP-0154343-A2 Adsorbent Research Development Corporation of Japan (JP) 1985-09-11 EP disclosed
US-4033940-A TERMINAL CYSTINE, REARRANGEMENT TO CYCLIC DISULFIDE ARMOUR PHARMACEUTICAL COMPANY (US) 1977-07-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080125581-A1 Methods and compositions for controlled polypeptide synthesis NGLY1, LNPEP, NPPA SLC1A1 313/4885SLC1A3 266/4885ALPI 963/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.